Treatment of Bronchial Asthma with Terbutaline Inhaled by Conespacer Combined with Positive Expiratory Pressure Mask

CHEST Journal ◽  
1991 ◽  
Vol 100 (2) ◽  
pp. 317-321 ◽  
Author(s):  
Erika Frischknecht-Christensen ◽  
Ole Nørregaard ◽  
Ronald Dahl
Keyword(s):  
Bronchial Asthma ◽  
Positive Expiratory Pressure

Inhaled β2-Agonist and Positive Expiratory Pressure in Bronchial Asthma

CHEST Journal ◽  
1993 ◽  
Vol 104 (4) ◽  
pp. 1108-1113 ◽  
Author(s):  
Erika Frischknecht Christensen ◽  
Ole Norregaard ◽  
Lone Winther Jensen ◽  
Ronald Dahl
Keyword(s):  
Bronchial Asthma ◽  
Β2 Agonist ◽  
Positive Expiratory Pressure

Pathogenesis of Bronchial Asthma

1950 ◽  
Vol 34 (6) ◽  
pp. 1829-1838 ◽  
Author(s):  
John J. Curry
Keyword(s):  
Bronchial Asthma

Atopic dermatitis: new horizons of therapy

2019 ◽  
Vol 1 (7) ◽  
pp. 29-32 ◽  
Author(s):  
L. S. Kruglova ◽  
E. M. Gensler
Keyword(s):  
Blood Pressure ◽  
Immune Response ◽  
Allergic Rhinitis ◽  
Atopic Dermatitis ◽  
Targeted Therapy ◽  
Inflammatory Response ◽  
Bronchial Asthma ◽  
New Horizons ◽  
The Past

Over the past decades, the first breakthrough milestone in the treatment of severe forms of atopic dermatitis (AD) has been targeted therapy aimed at inhibiting IL-4 and IL-13. This was made possible thanks to advances in the understanding of the pathogenesis of AD, the driver of which is the Th2-type immune response, which also underlies such manifestations of atopy as bronchial asthma, allergic rhinitis, and polynosis. In the case of the Th2-type immune response, cytokines IL-4 and IL-13 are secreted, which are the main promoters of the inflammatory response in AD. Inhibition of IL-4 and IL-13 leads to the prevention of inflammation and is an effective approach to therapy. The use of therapy aimed at inhibition of cytokines allows you to effectively cope with the manifestations of severe and moderately severe blood pressure.

Sign in / Sign up

Export Citation Format

Share Document